pharmaphorum March 18, 2025
Strong support from pharma groups including Amgen, Bristol Myers Squibb and Pfizer has allowed European venture capital firm Sofinnova Partners to close a new biotech fund with €165 million ($180 million) at its disposal.
The Biovelocita II fund builds on an impressive €1.2 billion raised by the VC last year and comes alongside the announcement this morning of three new biotech startups that have come into being with the help of Sofinnova backing.
In a statement, it said the fund – now claimed to be the largest Pan-European biotech accelerator – had exceeded its target and marks “a significant expansion of Sofinnova’s biotech acceleration strategy, extending beyond Italy to include France, the UK, and Denmark, with ambitions to further reach...
Today's Sponsors
Today's Sponsor